Markets:

Overview

News

Currencies

International

Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

116.05 -3.72 (-3.11%)

Streaming Delayed Price Updated: 10:08 AM EDT, Apr 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know

March 27, 2026

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Via StockStory

1 High-Flying Stock with Solid Fundamentals and 2 We Avoid

March 24, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...

Via StockStory

1 Cash-Heavy Stock to Target This Week and 2 We Question

March 19, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

Repligen Corp (NASDAQ:RGEN) Stock Falls Despite Q4 Earnings Beat as 2026 Guidance Disappoints ↗

February 24, 2026

Via Chartmill

Topics Earnings

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

March 15, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

2 Growth Stocks Set to Flourishand 1 We Turn Down

March 13, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

Via StockStory

3 Profitable Stocks We Keep Off Our Radar

March 10, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Brown Capital Dumps 190,000 AppFolio Shares Worth $45.1 Million ↗

March 06, 2026

Via The Motley Fool

AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know

March 06, 2026

Via StockStory

Topics Economy

3 Healthcare Stocks We’re Skeptical Of

March 02, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Via StockStory

3 Reasons to Avoid RGEN and 1 Stock to Buy Instead

March 02, 2026

Repligen trades at $124.97 and has moved in lockstep with the market. Its shares have returned 7.6% over the last six months while the S&P 500 has gained 6.6...

Via StockStory

Topics Stocks Supply Chain

Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know

February 27, 2026

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures.

Via StockStory

Topics Economy Stocks

Repligen (RGEN) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

Repligen (RGEN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings World Trade

Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations

February 24, 2026

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.1% year on year to $197.9 million. The...

Via StockStory

Repligen (RGEN) To Report Earnings Tomorrow: Here Is What To Expect

February 22, 2026

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

2 of Wall Street’s Favorite Stocks Worth Investigating and 1 We Avoid

February 19, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

3 Volatile Stocks Walking a Fine Line

February 02, 2026

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced...

Via StockStory

2 Cash-Producing Stocks to Target This Week and 1 We Ignore

January 28, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

3 Reasons to Sell RGEN and 1 Stock to Buy Instead

January 26, 2026

Repligen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.3%. The stock now trades at $163.29, marking a 36.5% gain. This was partly due to its solid...

Via StockStory

Topics Stocks

3 High-Flying Stocks That Fall Short

January 18, 2026

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,...

Via StockStory

Why Repligen (RGEN) Shares Are Sliding Today

January 14, 2026

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 3.9% in the afternoon session after the company presented at the JPMorgan Healthcare Conference and shared its sales...

Via StockStory

Topics Artificial Intelligence

1 Cash-Heavy Stock to Target This Week and 2 Facing Challenges

January 05, 2026

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

1 Volatile Stock to Target This Week and 2 We Turn Down

December 07, 2025

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor...

Via StockStory

Why Repligen (RGEN) Stock Is Trading Up Today

November 21, 2025

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 5.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate...

Via StockStory

Topics Artificial Intelligence Economy Stocks

Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Via StockStory

Topics Artificial Intelligence Stocks

3 Cash-Producing Stocks We Approach with Caution

November 10, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN)

November 06, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers.

Via StockStory

5 Revealing Analyst Questions From Repligen’s Q3 Earnings Call

November 04, 2025

Repligen’s third quarter saw revenue and non-GAAP profit exceed Wall Street expectations, yet the market responded negatively. Management attributed the quarter’s strong top-line performance to...

Via StockStory

Topics Earnings

3 Hyped Up Stocks with Open Questions

October 30, 2025

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Via StockStory

RGEN Q3 Deep Dive: Robust Product Demand Offset by Margin Pressures and Guidance Reset

October 29, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) announced better-than-expected revenue in Q3 CY2025, with sales up 21.9% year on year to $188.8 million. The company’s full-year...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.